Novel N-(4-piperidinyl)benzamide antimalarials with mammalian protein farnesyltransferase inhibitory activity

Chemical and Pharmaceutical Bulletin

Volumn 53, Issue 10, 2005, Pages 1324-1326

  Ryckebusch, Adina ^a   Gilleron, Pauline ^a   Millet, Régis ^a   Houssin, Raymond ^a   Lemoine, Amélie ^a   Pommery, Nicole ^a   Grellier, Philippe ^b   Sergheraert, Christian ^c   Hénichart, Jean Pierre ^a  

^a Faculté des Sciences Pharmaceutiques et Biologiques Université de Lille   (France)

^b MUSÉUM NATIONAL D'HISTOIRE NATURELLE   (France)

^c CNRS   (France)

Author keywords

Farnesyltransferase; Inhibitor; Malaria; N (4 piperidinyl) benzamide derivative; Plasmodium falciparum

Indexed keywords

BENZAMIDE DERIVATIVE; FARNESYL TRANS TRANSFERASE; PROTEIN FARNESYLTRANSFERASE INHIBITOR;

ANTIMALARIAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DESIGN; DRUG SYNTHESIS; DRUG TARGETING; ENZYME INHIBITION; IN VITRO STUDY; NONHUMAN; PLASMODIUM FALCIPARUM;

ALKYL AND ARYL TRANSFERASES; ANIMALS; ANTIMALARIALS; BENZAMIDES; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MICE; MOLECULAR STRUCTURE; PARASITIC SENSITIVITY TESTS; PLASMODIUM FALCIPARUM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 26444570874     PISSN: 00092363     EISSN: 13475223     Source Type: Journal    
DOI: 10.1248/cpb.53.1324     Document Type: Article

References (27)

1. Ridley G. R., Nature (London), 415, 686-692 (2002).
2. Fidock D. A., Rosenthal P. J., Croft S. L., Brun R., Nwaka S., Nat. Rev. Drug Discov., 3, 509-520 (2004).
3. Caponigro F., Casale M., Bryce J., Expert Opin. Investig. Drugs, 12, 943-954 (2003).
4. Chakrabarti D., Azam T., DelVecchio C., Qiu L., Park Y.-i., Allen C. M., Mol. Biochem. Parasitol., 94, 175-184 (1998).
5. Chakrabarti D., Da Silva T., Barger J., Paquette S., Patel H., Patterson S., Allen C. M., J. Biol. Chem., 277, 42066-42073 (2002).
6. Carrico D., Ohkanda J., Kendrick H., Yokoyama K., Blaskovich M. A., Bucher C. J., Buckner F. S., Van Voorhis W. C., Chakrabarti D., Croft S. L., Gelb M. H., Sebti S. M., Hamilton A. D., Bioorg. Med. Chem., 12, 6517-6526 (2004).
7. Reid T. S., Beese L. S., Biochemistry, 43, 6877-6884 (2004).
8. Mackay H. J., Hoekstra R., Eskens F. A., Loos W. J., Crawford D., Voi M., Van Vreckem A., Evans T. R., Verweij J., Clin. Cancer Res., 10, 2636-2644 (2004).
9. Ryan D. P., Eder J. P., Jr., Puchlaski T., Seiden M. V., Lynch T. J., Fuchs C. S., Amreim P. C., Sonnichsen D., Supko J. G., Clark J. W., Clin. Cancer Res., 10, 2222-2230 (2004).
10. Johnston S. R., IDrugs, 6, 72-78 (2003).
11. Hunt J. T., Ding C. Z., Batorsky R., Bednarz M., Bhide R., Cho Y., Chong S., Chao S., Gullo-Brown J., Guo P., Kim S. H., Lee F. Y., Leftheris K., Miller A., Mitt T., Patel M., Penhallow B. A., Ricca C., Rose W. C., Schmidt R., Slusarchyk W. A., Vite G., Manne V., J. Med. Chem., 43, 3587-3595 (2000).
12. Windsor W. T., Weber P. C., Wang J. J.-S., Strickland C. O., Njoroge F. G., Guzi T. J., Girijavallabhan V. M., Ferreira J. A., Desai J. A., Cooper A. B., Gelb M., PCT Int. Appl., WO 02/056884 (2002) [Chem. Abstr., 137, 125178 (2002)].
13. Windsor W. T., Weber P. C., Strickland C. O., Girijavallabhan V. M., PCT Int. Appl., WO 02/080895 (2002) [Chem. Abstr., 137, 304744 (2002)].
14. Houssin R., Pommery J., Salaün M.-C., Deweer S., Goossens J.-F., Chavatte P., Hénichart J.-P., J. Med. Chem., 45, 533-536 (2002).
15. Millet R., Domarkas J., Houssin R., Gilleron P., Goossens J.-F., Chavatte P., Logé C., Pommery N., Pommery J., Hénichart J.-P., J. Med. Chem., 47, 6812-6820 (2004).
16. Anthony N. J., Gomez R. P., Schaber M. D., Mosser S. D., Hamilton K. A., O'Neill T. J., Koblan K. S., Graham S. L., Hartman G. D., Shah D., Rands E., Koh N. E., Gibbs J. B., Oliff A. I., J. Med. Chem., 42, 3356-3368 (1999).
17. Williams T. M., Bergman J. M., Brashear K., Breslin M. J., Dinsmore C. J., Hutchinson J. H., MacTough S. C., Stump C. A., Wei D. D., Zartman C. B., Bogusky M. J., Culberson J. C., Buser-Doepner C., Davide J., Greenberg I. B., Hamilton K. A., Koblan K. S., Kohl N. E., Liu D., Lobell R. B., Mosser S. D., O'Neill T. J., Rands E., Schaber M. D., Wilson F., Senderak E., Motzel S. L., Gibbs J. B., Graham S. L., Heimbrook D. C., Hartman G. D., Oliff A. I., Huff J. R., J. Med. Chem., 42, 3779-3784 (1999).
18. Ohkanda J., Lockman J. W., Yokoyama K., Gelb M. H., Croft S. L., Kendrick H., Harrell M. I., Feagin J. E., Blaskovich M. A., Sebti S. M., Hamilton A. D., Bioorg. Med. Chem. Lett., 11, 761-764 (2001).
19. Wiesner J., Ortmann R., Mitsch A., Wißner P., Sattler I., Jomaa H., Schlitzer M., Pharmazie, 58, 289-290 (2003).
20. Khan S. G., Mukthar H., Agarwal R., J. Biochem. Biophys. Methods, 30, 133-144 (1995).
21. Cassidy P. B., Dolence J. M., Poulter C. D., Methods Enzymol., 250, 30-43 (1995).
22. 50 was obtained from the drug concentration-response curve and the results were expressed as mean±standard deviations, determined from several independent experiments. The DMSO concentration never exceeded 0.1% and did not inhibit parasite growth.
23. Trager W., Jensen J. B., Science, 193, 673-675 (1976).
24. Desjardins R. E., Canfield C. J., Haynes J. D., Chulay J. D., Antimicrob. Agents Chemother., 16, 710-718 (1979).
25. Wiesner J., Kettler K., Sakowski J., Ortmann R., Katzin A. M., Kimura E. A., Silber K., Klebe G., Jomaa H., Schlitzer M., Angew. Chem., Int. Ed. Engl., 43, 251-254 (2004).
26. Lew V. L., Tiffert T., Ginsburg H., Trends Parasitol., 18, 156 (2002).
27. Cell culture and growth assays. DLD-1 (human colon adenocarcinoma transformed by K-Ras oncogene) and L-1210 (mouse lymphocytic leukaemia) were cultured in RPMI medium with 10% fetal calf serum. Cells were allowed to grow for 72 h in 96-microwell plates and then treated with a range of inhibitor concentrations for 72 h (final 1‰ DMSO concentration). Cell growth was measured by means of the colorimetric MTT assay.